Novel human erythrovirus associated with transient aplastic anemia

Laboratoire de Virologie, Hôpital Armand Trousseau (EA 2391 UFR Saint-Antoine), 75 571 Paris Cedex 12, France.
Journal of Clinical Microbiology (Impact Factor: 3.99). 08/1999; 37(8):2483-7.
Source: PubMed


Erythrovirus (formerly parvovirus) B19 causes a wide range of diseases in humans, including anemia due to aplastic crisis. Diagnosis of B19 infection relies on serology and the detection of viral DNA by PCR. These techniques are usually thought to detect all erythrovirus field isolates, since the B19 genome is known to undergo few genetic variations. We have detected an erythrovirus (V9) markedly different from B19 in the serum and bone marrow of a child with transient aplastic anemia. The B19 PCR assay yielded a product that hybridized only very weakly to the B19-specific probe and whose sequence diverged more from those of 24 B19 viruses (11 to 14%) than the divergence found within the B19 group (</=6.65%). Restriction enzyme analysis of the V9 genome revealed that this genetic divergence extended beyond the amplified region. Interestingly, serological tests failed to demonstrate a response characteristic of acute B19 infection. V9 could be a new erythrovirus, and new diagnostic tests are needed for its detection.

Download full-text


Available from: Antoine Garbarg-chenon
  • Source
    • "Parvovirus B19 (B19V), a member of the genus Erythrovirus within the Parvoviridae family, has been grouped into three distinct genotypes: (i) genotype 1, with subtypes 1a (the prototypic virus) and 1b, (ii) genotype 2 (A6 and LaLi strains) and (iii) genotype 3, with subtypes 3a (V9 strains) and 3b (D91.1 strains) (Nguyen et al. 1999, 2002, Servant et al. 2002, Fauquet et al. 2005). B19V primarily infects erythroid cells, leading to transient inhibition of erythropoiesis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunocompromised patients may develop severe chronic anaemia when infected by human parvovirus B19 (B19V). However, this is not the case in human immunodeficiency virus (HIV)-infected patients with good adherence to highly active antiretroviral treatment (HAART). In this study, we investigated the clinical evolution of five HIV-infected patients receiving HAART who had B19V infections confirmed by serum polymerase chain reaction. Four of the patients were infected with genotype 1a strains and the remaining patient was infected with a genotype 3b strain. Anaemia was detected in three of the patients, but all patients recovered without requiring immunoglobulin and/or blood transfusions. In all cases, the attending physicians did not suspect the B19V infections. There was no apparent relationship between the infecting genotype and the clinical course. In the HAART era, B19V infections in HIV-positive patients may be limited, subtle or unapparent.
    Full-text · Article · Apr 2014 · Memórias do Instituto Oswaldo Cruz
  • Source
    • "Genotype 2 has since been found in human solid tissues but only sporadically in blood and seems to have disappeared from wide circulation after the 1970s (Blumel et al, 2005; Norja et al, 2006; Manning et al, 2007; Grabarczyk et al, 2011, Koppelman et al, 2011). The genotype 3 virus was found in France in the serum and bone marrow of a child with transient aplastic anaemia (Nguyen et al, 1999). Following its discovery , genotype 3 has been reported to be endemic in Ghana and Brazil (Candotti et al, 2004; Sanabani et al, 2006; Freitas et al, 2008; Keller et al, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The introduction of dual viral inactivation of clotting factor concentrates has practically eliminated infections by viruses associated with significant pathogenicity over the last 20 years. Despite this, theoretical concerns about transmission of infection have remained, as it is known that currently available viral inactivation methods are unable to eliminate parvovirus B19 or prions from these products. Recently, concern has been raised following the identification of the new parvoviruses, human parvovirus 4 (PARV4) and new genotypes of parvovirus B19, in blood products. Parvoviruses do not cause chronic pathogenicity similar to human immunodeficiency virus or hepatitis C virus, but nevertheless may cause clinical manifestations, especially in immunosuppressed patients. Manufacturers should institute measures, such as minipool polymerase chain reaction testing, to ensure that their products contain no known viruses. So far, human bocavirus, another new genus of parvovirus, has not been detected in fractionated blood products, and unless their presence can be demonstrated, routine testing during manufacture is not essential. Continued surveillance of the patients and of the safety of blood products remains an important ongoing issue.
    Full-text · Article · Oct 2012 · British Journal of Haematology
  • Source
    • "Prototype B19V replicates exclusively in erythroid progenitors of human bone marrow, and produces extraordinarily high virus yields in blood during the early phase of infection (Anderson et al., 1985; Enders et al., 2006; Ozawa et al., 1986). In contrast, high-titers of genotype-2 and genotype-3 are rarely identified (Blumel et al., 2005; Liefeldt et al., 2005; Nguyen et al., 1999, 2002; Servant et al., 2002). More importantly, the genotype-2 variant often persistently presents in skin; and genotype-3 has been suggested to have remained absent from wide circulation in Europe (Norja et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We have characterized the transcription profiles of parvovirus B19 (B19V) genotype-2 A6 and genotype-3 V9 variants. The A6 RNA profile differs from that of the prototype B19V in both B19V non-permissive and permissive cells, whereas the overall profile of the V9 RNA in these cells is similar to that of the prototype. A unique feature we have identified is that the genotype-2 A6 variant used only one splice acceptor to remove the first intron. We also demonstrated that the inverted terminal repeats (ITRs) of the prototype B19V support replication of the V9 genome, which produces infectious virus, but not that of the A6 genome, in B19V-permissive cells. Similar to the proapoptotic nature of the prototype B19V large non-structural protein (NS1), the A6 and V9 NS1 proteins also are potent inducers of apoptosis in B19V-permissive cells.
    Preview · Article · Nov 2009 · Virology
Show more